Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

Abstract Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by marrow fibrosis, splenomegaly, constitutional symptoms and cytopenia with a proinflammatory and profibrotic cytokine phenotype involving the JAK-STAT pathway. Ruxolitinib is a JAK 1/2 inhibitor with proven efficacy on sple...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Villar, Emmanuel Curis, Marie-Hélène Schlageter, Nelly Bosselut, Amandine Charbonnier, Marie-Thérèse Rubio, Pascal Turlure, Hélène Labussière, Jacques-Olivier Bay, Jérome Cornillon, Laure Vincent, Corentin Orvain, Jean-Jacques Kiladjian, David Michonneau, Gérard Socié, Marie Robin
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Myelofibrosis
Cytokines
Ruxolitinib
Graft-versus-host disease
Online Access:https://doi.org/10.1007/s00262-025-04046-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04046-8

Similar Items